Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Perioperative mortality · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
Fibrin‐based haemostatic agents showed no clear difference in serious adverse events Median compared with non‐fibrin‐based haemostatic agents (low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with non‐fibrin‐based haemostatic agents (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Recurrent VTE · participants with diagnosed DVT
Oral DTIs showed no clear difference in recurrent VTE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review